SCHEMBL6316240

SCHEMBL6316240

COc1ccc(OC)c(C(=O)C2CCC(OC)CC2c2ccc(F)c(OOP(=O)(O)O)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 1/20 0.36
KDM1A O60341 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CPS1 P31327 4/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GPR6 P46095 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GFER P55789 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314627 0.95 LMNA (0.36) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6315408 0.94 MAPT (0.38) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6322855 0.92 MAPT (0.39) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6315434 0.92 MAPT (0.41) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6321011 0.91 MAPT (0.36) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6317115 0.89 MAPT (0.35) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6323423 0.88 KDM1A (0.38) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6315331 0.88 MAPT (0.38) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6316369 0.86 MAPT (0.37) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL6315313 0.85 MAPT (0.41) LMNAHTTALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887904-B2 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-05-03 US disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR LMNA 3280/4885HTT 2064/4885ALDH1A1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.